Model-Guided Design Space Development for a Drug Substance Manufacturing Process
暂无分享,去创建一个
Alan D. Braem | Srinivas Tummala | Justin L. Burt | Antonio Ramirez | Boguslaw Mudryk | Lucius T. Rossano
[1] John Lepore,et al. PQLI Design Space , 2008, Journal of Pharmaceutical Innovation.
[2] K. Siu,et al. Formation of [M − nH + mNa](m−n)+ and [M − nH + mK](m−n)+ ions in electrospray mass spectrometry of peptides and proteins , 2000, Journal of the American Society for Mass Spectrometry.
[3] Carlo Castagnoli,et al. Application of Quality by Design Principles for the Definition of a Robust Crystallization Process for Casopitant Mesylate , 2010 .
[4] Roger Nosal,et al. PQLI Key Topics - Criticality, Design Space, and Control Strategy , 2008, Journal of Pharmaceutical Innovation.
[5] Michael B. Mitchell,et al. Current thoughts on critical process parameters and API synthesis , 2005 .
[6] Lawrence X. Yu. Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control , 2008, Pharmaceutical Research.
[7] Bernard McGarvey,et al. The Use of Routine Process Capability for the Determination of Process Parameter Criticality in Small-molecule API Synthesis , 2008, Journal of Pharmaceutical Innovation.
[8] Alan D. Braem,et al. An Example of Utilizing Mechanistic and Empirical Modeling in Quality by Design , 2010, Journal of Pharmaceutical Innovation.
[9] Evan L. Allred,et al. Amidation of Esters with Amides in the Presence of Methoxide Ion , 1965 .
[10] Roger Nosal,et al. API Quality by Design Example from the Torcetrapib Manufacturing Process , 2007, Journal of Pharmaceutical Innovation.